The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schade, A. E.
Right arrow Articles by Levine, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schade, A. E.
Right arrow Articles by Levine, A. D.
The Journal of Immunology, 2004, 172: 5828-5832.
Copyright © 2004 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: Extracellular Signal-Regulated Kinases 1/2 Function as Integrators of TCR Signal Strength 1

Andrew E. Schade* and Alan D. Levine2,*,{dagger},{ddagger}

Departments of * Pathology, {dagger} Medicine, and {ddagger} Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106

Altered signaling through the TCR is currently showing promise for immunotherapy. However, the molecular mechanisms are not completely understood. Therefore, we investigated whether varying the strength of TCR engagement in various human T cells would yield different second messenger responses. The kinetics and duration of extracellular signal-regulated kinase (ERK) activation, central to multiple cellular responses, are distinctly dependent on the T cell activation state (naive vs effector), strength of TCR cross-linking, and input from the phosphatidylinositol-3 kinase pathway, which is regulated by cytokines and growth factors. Moreover, the duration of ERK activation affects c-Fos expression, a component of the AP-1 transcription complex. Thus, the character of ERK activation, transient or sustained, acts as a signal integrator to quantify the strength of TCR engagement and direct the cellular response.




This article has been cited by other articles:


Home page
BloodHome page
A. E. Schade, G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Blood, February 1, 2008; 111(3): 1366 - 1377.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C.-P. Liu, Y.-C. Kuo, C.-C. Shen, M.-H. Wu, J.-F. Liao, Y.-L. Lin, C.-F. Chen, and W.-J. Tsai
(S)-Armepavine inhibits human peripheral blood mononuclear cell activation by regulating Itk and PLC{gamma} activation in a PI-3K-dependent manner
J. Leukoc. Biol., May 1, 2007; 81(5): 1276 - 1286.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. L. Kemp, L. Wille, C. L. Lewis, L. B. Nicholson, and D. A. Lauffenburger
Quantitative Network Signal Combinations Downstream of TCR Activation Can Predict IL-2 Production Response
J. Immunol., April 15, 2007; 178(8): 4984 - 4992.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Ibanez, M.-R. Sarrias, M. Farnos, I. Gimferrer, C. Serra-Pages, J. Vives, and F. Lozano
Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface Receptor
J. Immunol., July 15, 2006; 177(2): 1152 - 1159.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski
Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis
Blood, June 15, 2006; 107(12): 4834 - 4840.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
O. Kogkopoulou, E. Tzakos, G. Mavrothalassitis, C. T. Baldari, F. Paliogianni, H. A. Young, and G. Thyphronitis
Conditional up-regulation of IL-2 production by p38 MAPK inactivation is mediated by increased Erk1/2 activity
J. Leukoc. Biol., May 1, 2006; 79(5): 1052 - 1060.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Rubenfeld, J. Guo, N. Sookrung, R. Chen, W. Chaicumpa, V. Casolaro, Y. Zhao, V. Natarajan, and S. Georas
Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells
Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L66 - L74.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. K. Robertson, L. R. Mireau, and H. L. Ostergaard
A Role for Phosphatidylinositol 3-Kinase in TCR-Stimulated ERK Activation Leading to Paxillin Phosphorylation and CTL Degranulation
J. Immunol., December 15, 2005; 175(12): 8138 - 8145.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Nekrasova, C. Shive, Y. Gao, K. Kawamura, R. Guardia, G. Landreth, and T. G. Forsthuber
ERK1-Deficient Mice Show Normal T Cell Effector Function and Are Highly Susceptible to Experimental Autoimmune Encephalomyelitis
J. Immunol., August 15, 2005; 175(4): 2374 - 2380.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. R. Clemmons and L. A. Maile
Interaction between Insulin-Like Growth Factor-I Receptor and {alpha}V{beta}3 Integrin Linked Signaling Pathways: Cellular Responses to Changes in Multiple Signaling Inputs
Mol. Endocrinol., January 1, 2005; 19(1): 1 - 11.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.